Nanjing Sai Taisi Biotechnology

Nanjing Sci-Tais Biotechnology is a clinical-stage biopharmaceutical company specializing in the development of next-generation cell therapies for solid tumors. The company utilizes its proprietary STAR-T (Synthetic T cell Antigen Receptor) platform, which is designed to overcome the limitations of traditional CAR-T therapies by enhancing T-cell infiltration and persistence in the tumor microenvironment. Their lead program, ST-001, targets Glypican-3 (GPC3) and is currently in Phase 1 clinical trials for the treatment of hepatocellular carcinoma. Sci-Tais is committed to advancing a diverse pipeline of CAR-T and TCR-T candidates to address significant unmet needs in oncology.